Abstract
Regenerative dermatology and 3D skin bioprinting have advanced rapidly over the past decade, offering new possibilities for restoring complex cutaneous architecture beyond the limitations of traditional grafting techniques. This review synthesizes evidence from twenty recent studies to evaluate technological innovations, biological strategies, and translational progress in the fabrication of functional human skin. The findings indicate a clear predominance of extrusion-based platforms, supported by emerging microfluidic, hybrid, and in situ systems that enhance structural fidelity and dynamic responsiveness. Bioinks have evolved from simple hydrogels to biologically instructive matrices, including GelMA-based formulations, alginate–gelatin composites, ECM-derived hydrogels, placental matrices, and peptide-functionalized biomaterials. These materials not only support high cell viability but also modulate angiogenesis, immune responses, and extracellular matrix organization. Multicellular strategies incorporating keratinocytes, fibroblasts, endothelial cells, pericytes, and stem cells demonstrate superior performance in vascular integration, tissue maturation, and appendage regeneration. Vascularization remains the critical determinant of clinical viability, with endothelial co-printing, sacrificial-channel scaffolds, and angiogenic bioinks emerging as complementary approaches to overcome diffusion limitations. Current applications are concentrated in wound healing, where bioprinted constructs improve closure and integration, and in disease modeling, where they enable physiologically relevant platforms for pharmacologic testing. In situ bioprinting represents a developing frontier for personalized bedside reconstruction. Collectively, the evidence shows that 3D bioprinting is transitioning toward translational readiness, supported by interdisciplinary advances and growing international participation, including key contributions from Mexico, Colombia, and Ecuador. Continued progress depends on refining vascular strategies, standardizing bioinks, and expanding collaborative research to ensure equitable future clinical implementation.

This publication has 18 references indexed in Scilit: